The present study will be conducted to test the hypothesis
that in combination with metformin, vildagliptin may
produce a greater improvement in glucose variability after
a submaximal exercise test, compared with glibenclamide.
Our general aim will be to evaluate glucose variability
after the submaximal exercise test in patients receiving
treatment with vildagliptin or glibenclamide. The specific
aims of this study are to evaluate the oxidative stress,
endothelial function, and metabolic and cardiovascular responses
to exercise in patients treated with vildagliptin or
glibenclamide.